News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,572 Results
Type
Article (42228)
Company Profile (266)
Press Release (692064)
Multimedia
Podcasts (119)
Webinars (20)
Section
Business (205256)
Career Advice (2057)
Deals (35723)
Drug Delivery (135)
Drug Development (81882)
Employer Resources (174)
FDA (16594)
Job Trends (15054)
News (347745)
Policy (32927)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2613)
Accelerated approval (55)
ADA (44)
Adcomms (29)
Allergies (187)
Alliances (49668)
ALS (221)
Alzheimer's disease (1820)
Antibody-drug conjugate (ADC) (502)
Approvals (17018)
Artificial intelligence (703)
ASCO (329)
Autoimmune disease (332)
Automation (58)
Bankruptcy (363)
Best Places to Work (11658)
BIOSECURE Act (21)
Biosimilars (228)
Biotechnology (171)
Bladder cancer (203)
Brain cancer (75)
Breast cancer (793)
Cancer (6188)
Cardiovascular disease (498)
Career advice (1747)
Career pathing (44)
CAR-T (352)
CDC (61)
Celiac Disease (3)
Cell therapy (945)
Cervical cancer (52)
Clinical research (71459)
Collaboration (2154)
Company closure (5)
Compensation (1465)
Complete response letters (84)
COVID-19 (2867)
CRISPR (114)
C-suite (1199)
Cystic fibrosis (155)
Data (8463)
Decentralized trials (3)
Denatured (28)
Depression (166)
Dermatology (94)
Diabetes (653)
Diagnostics (7008)
Digital health (62)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (339)
Drug pricing (211)
Drug shortages (31)
Duchenne muscular dystrophy (299)
Earnings (92214)
Editorial (69)
Employer branding (22)
Employer resources (153)
Events (120457)
Executive appointments (1109)
FDA (20482)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (35)
Funding (1802)
Gene editing (242)
Generative AI (60)
Gene therapy (745)
GLP-1 (1106)
Government (4821)
Grass and pollen (6)
Guidances (415)
Healthcare (19169)
Hematology (192)
HIV (85)
Huntington's disease (58)
IgA nephropathy (110)
Immunology and inflammation (296)
Immuno-oncology (101)
Indications (204)
Infectious disease (3234)
Inflammatory bowel disease (222)
Inflation Reduction Act (14)
Influenza (140)
Intellectual property (311)
Interviews (323)
IPO (16683)
IRA (53)
Job creations (3689)
Job search strategy (1448)
JPM (62)
Kidney cancer (20)
Labor market (109)
Layoffs (576)
Leadership (42)
Legal (8011)
Liver cancer (103)
Longevity (34)
Lung cancer (820)
Lymphoma (464)
Machine learning (61)
Management (59)
Manufacturing (1106)
MASH (208)
Medical device (13973)
Medtech (14125)
Mergers & acquisitions (20328)
Metabolic disorders (1649)
mRNA (232)
Multiple sclerosis (194)
NASH (17)
Neurodegenerative disease (446)
Neuropsychiatric disorders (107)
Neuroscience (3412)
Neurotech (1)
NextGen: Class of 2026 (6538)
Non-profit (4543)
Now hiring (79)
Obesity (769)
Opinion (299)
Ovarian cancer (235)
Pain (262)
Pancreatic cancer (335)
Parkinson's disease (384)
Partnered (33)
Patents (625)
Patient recruitment (727)
Peanut (66)
People (59943)
Pharmaceutical (59)
Pharmacy benefit managers (35)
Phase 1 (22273)
Phase 2 (31472)
Phase 3 (23460)
Pipeline (9483)
Policy (341)
Postmarket research (2575)
Preclinical (9468)
Press Release (64)
Prostate cancer (332)
Psychedelics (58)
Radiopharmaceuticals (340)
Rare diseases (1137)
Real estate (5988)
Recruiting (71)
Regulatory (25725)
Reports (56)
Research institute (2425)
Resumes & cover letters (358)
Rett syndrome (42)
RNA editing (23)
RSV (94)
Schizophrenia (182)
Series A (303)
Series B (222)
Service/supplier (11)
Sickle cell disease (119)
Special edition (27)
Spinal muscular atrophy (167)
Sponsored (48)
Startups (3668)
State (2)
Stomach cancer (18)
Supply chain (133)
Tariffs (94)
The Weekly (89)
Vaccines (1195)
Venture capital (117)
Weight loss (498)
Women's health (133)
Worklife (20)
Date
Today (55)
Last 7 days (568)
Last 30 days (2656)
Last 365 days (30437)
2026 (15078)
2025 (30248)
2024 (35288)
2023 (40142)
2022 (51239)
2021 (55812)
2020 (54164)
2019 (46582)
2018 (35073)
2017 (32214)
2016 (31594)
2015 (37611)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (750)
Alabama (93)
Alaska (7)
Arizona (360)
Arkansas (14)
Asia (39975)
Australia (6542)
California (13800)
Canada (3889)
China (1456)
Colorado (590)
Connecticut (606)
Delaware (431)
Europe (86534)
Florida (2062)
Georgia (440)
Hawaii (3)
Idaho (63)
Illinois (1124)
India (94)
Indiana (624)
Iowa (23)
Japan (574)
Kansas (132)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1645)
Massachusetts (9878)
Michigan (371)
Minnesota (745)
Mississippi (6)
Missouri (147)
Montana (33)
Nebraska (29)
Nevada (146)
New Hampshire (84)
New Jersey (3619)
New Mexico (30)
New York (3614)
North Carolina (1739)
North Dakota (9)
Northern California (6961)
Ohio (412)
Oklahoma (23)
Oregon (41)
Pennsylvania (2751)
Puerto Rico (29)
Rhode Island (51)
South America (1118)
South Carolina (86)
South Dakota (2)
Southern California (5458)
Tennessee (220)
Texas (2203)
United States (48647)
Utah (407)
Vermont (1)
Virginia (334)
Washington D.C. (81)
Washington State (1100)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
734,572 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
May 12, 2026
·
2 min read
·
Tristan Manalac
Cancer
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.
June 2, 2026
·
6 min read
·
Brianna Abbott
Earnings
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
May 5, 2026
·
3 min read
·
Annalee Armstrong
Obesity
ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market
Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.
June 8, 2026
·
4 min read
·
Tristan Manalac
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S. last year.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
China
Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent
Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.
May 29, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
·
1 min read
·
Annalee Armstrong
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat
Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.
May 5, 2026
·
2 min read
·
Annalee Armstrong
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
1 of 73,458
Next
